Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GK01 + PD-1 monoclonal antibody
- Development stage
- Unknown
- Lead developer
- Tianjin Medical University Cancer Institute and Hospital
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cell Therapies
- Administration
- Intravenous
01
Overview
GK01 + PD-1 monoclonal antibody is an investigational combination therapy being developed by the Tianjin Medical University Cancer Institute and Hospital for the treatment of advanced solid tumors. The regimen consists of GK01, a cell-based injection, administered in conjunction with a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor. GK01 is a cell therapy product, while the PD-1 antibody serves as an immune checkpoint inhibitor designed to enhance the body's anti-tumor immune response by preventing the suppression of T-cell activity. This combination is currently being evaluated in a Phase 1 clinical trial to determine its safety, pharmacokinetic profile, and preliminary efficacy in patients with refractory or advanced malignancies.
- Other names
- GK01 cell injection in combination with a PD-1 monoclonal antibodyGK-01 cell injection in combination with a PD-1 monoclonal antibodyGK 01 cell injection in combination with a PD-1 monoclonal antibody
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on GK01 + PD-1 monoclonal antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GK01 + PD-1 monoclonal antibody.